{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:01:56Z","timestamp":1791316916890,"version":"4.3.1"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Metalloproteinases (MMPs) are involved in many distinct processes in the liver. Matrix metalloproteinase-3 (MMP-3) plays an important role in connective tissue remodeling, degradation of collagen (types II, III, IV, IX, and X), proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9. Primary biliary cholangitis (PBC) is a cholestatic, autoimmune liver disease, characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and liver failure. Fibrosis is the result of an imbalance between production and degradation of the extracellular matrix surrounding hepatocytes. Our aim in the present study was to determine whether the measurement of serum MMP-3 is clinically useful for assessing ongoing liver fibrosis in patients with PBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MMP-3 concentration was determined in 182 PBC patients and 80 non-PBC controls using a commercially available ELISA kit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher concentrations of MMP-3 were found in 61% of PBC patients. PBC subjects had greater MMP-3 levels than controls: 68.9 \u00b1 62.6 vs 21.3 \u00b1 7.4 ng\/mL, p &amp;lt; 0.001 for healthy subjects; 68.9 \u00b1 62.6 vs 22.7 \u00b1 7.6 ng\/mL, p = 0.022 for autoimmune hepatitis controls; and 68.9 \u00b1 62.6 vs 37.2 \u00b1 17.4 ng\/mL, p = 0.002 for primary sclerosing cholangitis controls. The serum MMP-3 concentration was significantly elevated in patients with higher bilirubin concentration (107.6 \u00b1 85.8 vs 61.6 \u00b1 46.1 ng\/mL, p &amp;lt; 0.001) and was correlated with the level of antimitochondrial antibodies specific for PBC. The concentration of MMP-3 in sera of PBC patients was also found to correlate with the state of liver fibrosis (OR = 4.3; p &amp;lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study demonstrated significantly higher MMP-3 levels in PBC patients than in healthy and pathological controls. Increased MMP-3 concentrations were positively correlated with various clinical and immunological parameters, and advanced liver fibrosis. The level of MMP-3 was associated with hepatic dysfunction and could play a role in the pathophysiology of hepatic fibrosis in PBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.885229","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T01:37:10Z","timestamp":1650591430000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis"],"prefix":"10.3389","volume":"13","author":[{"given":"Alicja","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Habior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary Biliary Cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1945919","article-title":"A Consensus Integrated Care Pathway for Patients With Primary Biliary Cholangitis: A Guideline-Based Approach to Clinical Care of Patients","volume":"15","author":"Hirschfield","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2018.03.004","article-title":"Primary Biliary Cholangitis: Diagnosis and Treatment","volume":"2","author":"Chew","year":"2018","journal-title":"Liver Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102328","article-title":"The Challenges of Primary Biliary Cholangitis: What Is New and What Needs To Be Done","volume":"105","author":"Beretta-Piccoli","year":"2019","journal-title":"J Autoimmun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2152\/jmi.64.7","article-title":"Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms","volume":"64","author":"Tsuneyama","year":"2017","journal-title":"J Med Investig"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-018-0515-9","article-title":"A Deviations in Peripheral Blood Cell Populations Are Associated With the Stage of Primary Biliary Cholangitis and Presence of Itching","volume":"66","author":"Cichoz-Lach","year":"2017","journal-title":"Arch Immunol Ther Ex"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL Clinical Practice Guidance: The Diagnosis and Management of Patients With Primary Biliary Cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: Practice Guidance From the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/HMER.S135337","article-title":"Biomarkers for Primary Biliary Holangitis: Current Perspectives","volume":"10","author":"Kouroumalis","year":"2018","journal-title":"Hepat Med: Evidence Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00309","article-title":"The Importance of Autoantibody Detection in Primary Biliary Cirrhosis","volume":"6","author":"Cancado","year":"2015","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/hep.30604","article-title":"Genome-Wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis","volume":"70","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics11040587","article-title":"Analysis of Autoantibodies Against Promyelocytic Leukemia Nuclear Body Com-Ponents and Biochemical Parameters in Sera of Patients With Primary Biliary Cholangitis","volume":"11","author":"Bauer","year":"2021","journal-title":"Diagnostics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2016.06.001","article-title":"The Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis","volume":"40","author":"Ozaslan","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.596","article-title":"PML Nuclear Body Component Sp140 is a Novel Autoantigen I Primary Biliary Cirrhosis","volume":"105","author":"Granito","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/erm.11.82","article-title":"Antinuclear Antibodies as Ancillary Markers in Primary Biliary Cirrhosis","volume":"12","author":"Granito","year":"2012","journal-title":"Expert Rev Mol Diagn"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13223-021-00539-0","article-title":"Autoantibodies to Speckled Protein Family in Primary Biliary Cholangitis","volume":"17","author":"Granito","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B17","article-title":"Meta-Analysis of Antinuclear Antibodies in Thediagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis","volume":"10","author":"Zhang","year":"2019","journal-title":"Hindawi Gastroent Res Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2019.39.3.291","article-title":"Detection of Autoantibodies Against Nucleoporin P62 in Sera of Patients With Primary Biliary Cholangitis","volume":"39","author":"Bauer","year":"2019","journal-title":"Ann Lab Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03172.x","article-title":"Antinuclear Antibodies Giving the \u2018Multiple Nuclear Dots\u2019 or the \u2018Rim-Like\/Membranous\u2019 Patterns: Diagnostic Accuracy for Primary Biliary Cirrhosis","volume":"24","author":"Granito","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15701","article-title":"Multifunctional Intracellular Matrix Metalloproteinases: Implications in Disease","volume":"288","author":"Bassiouni","year":"2021","journal-title":"FEBS J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/cells9051076","article-title":"Structure and Function of Human Matrix","volume":"9","author":"Laronha","year":"2020","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00451-x","article-title":"Epigenetic Regulation of Matrix Metalloproteinases in Inflammatory Diseases: A Narrative Review","volume":"10","author":"He","year":"2020","journal-title":"Cell Biosci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.02.005","article-title":"Biochemical and Biological Attributes of Matrix Metalloproteinases","volume":"147","author":"Cui","year":"2017","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051212","article-title":"Matrix Metalloproteinases and Liver Fibrosis (Translational Aspects)","author":"Roeb","year":"2020","journal-title":"Matrix Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2007.06.006","article-title":"MMPs as Therapeutic Targets\u2014Still a Viable Option","volume":"19","author":"Fingleton","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1242\/dmm.012062","article-title":"Diverse Functions of Matrix Metalloproteinases During Fibrosis","volume":"7","author":"Giannandrea","year":"2014","journal-title":"Dis Model Mech"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)30785-9","article-title":"Fibro-Check: A Combination of Direct and Indirect Markers for Liver Fibrosis Staging in Chronic Hepatitis C Patients","volume":"14","author":"Attallah","year":"2015","journal-title":"Ann Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1042\/CS20030098","article-title":"Expression and Coordinated Regulation of Matrix Metalloproteinases in Chronic Hepatitis C and Hepatitis C Virus-Induced Liver Cirrhosis Clin","volume":"105","author":"Lichtinghagen","year":"2003","journal-title":"Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.10.02","article-title":"Clinical Presentation of Alcoholic Liver Disease and non-Alcoholic Fatty Liver Disease: Spectrum and Diagnosis","volume":"5","author":"Sharma","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5604\/12321966.1152088","article-title":"Activity of MMP-2, MMP-8 and MMP-9 in Serum as a Marker of Progression of Alcoholic Liver Disease in People From Lublin Region, Eastern Poland","volume":"22","author":"Prystupa","year":"2015","journal-title":"Ann Agric Environ Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1589","article-title":"Serum Matrix Metalloproteinase 7 Is a Diagnostic Biomarker of Biliary Injury and Fibrosis in Pediatric Autoimmune Liver Disease","volume":"4","author":"Lam","year":"2020","journal-title":"Hepatol Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2017.09.004","article-title":"Matrix Metalloproteinases (MMPs) in Liver Diseases","volume":"7","author":"Naim","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2017.12.012","article-title":"Matrix Metalloproteinases and Liver Fibrosis (Translational Aspects)","author":"Roeb","year":"2018","journal-title":"Matrix Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3350\/cmh.2017.0030","article-title":"Serum Matrix Metalloproteinase-1 Level Represents Disease Activity as Opposed to Fibrosis in Patients With Histologically Proven Nonalcoholic Steatohepatitis","volume":"24","author":"Ando","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41598-021-82315-z","article-title":"Serum Matrix Metalloproteinase 7 (MMP7) Is a Biomarker of Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease","volume":"11","author":"Irvine","year":"2021","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024753","article-title":"MMP Mediated Degradation of Type VI Collagen Is Highly Associated With Liver Fibrosis\u2014Identification and Validation of a Novel Biochemical Marker Assay","volume":"6","author":"Veidal","year":"2011","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1595","article-title":"Involvement of Matrix Metalloproteinase Type-3 in Hepatocyte Growth Factor-Induced Invasion of Human Hepatocellular Carcinoma Cells","volume":"97","author":"Monvoisin","year":"2002","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i2.218","article-title":"Production and Activity of Matrix Metalloproteinases During Liver Fibrosis Progression of Chronic Hepatitis C Patients","volume":"13","author":"Martinez-Castillo","year":"2021","journal-title":"World J Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051212","article-title":"Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases","volume":"9","author":"Geervliet","year":"2020","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-94-007-7675-3_6","article-title":"Type VI Collagen: Its Biology and Value as a Biomarker of Hepatic Fibrosis","volume":"1","author":"Mak","year":"2014","journal-title":"Austin Biomark Diagn"},{"key":"B41","article-title":"Expression of Matrix Proteinases During Human Intrahepatic Bile Duct Development. A Possible Role in Biliary Cell Migration","volume":"147","author":"Terada","year":"1995","journal-title":"Am J Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060005","article-title":"Matrix Metalloproteinase 3 Is Present in the Cell Nucleus and Is Involved in Apoptosis","volume":"169","author":"Si-Tayeb","year":"2006","journal-title":"Am J Pathol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-17552","article-title":"Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells","volume":"21","author":"Benyon","year":"2001","journal-title":"Semin Liver Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2000.279.2.G245","article-title":"Fibrogenesis II Metalloproteinases and Their Inhibitors in Liver Fibrosis","volume":"279","author":"Arthur","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and Function of Matrix Metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","journal-title":"Cardiovasc Re"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0279fje","article-title":"Rat Liver Injury Following Normothermic Ischemia Is Prevented by a Phosphinic Matrix Metalloproteinase Inhibitor","volume":"16","author":"Cursio","year":"2002","journal-title":"FASEB J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.03860.x","article-title":"Association of Functional Gene Polymorphisms of Matrix Metalloproteinase (MMP)-1, MMP-3 and MMP-9 With the Progression of Chronic Liver Disease","volume":"20","author":"Okamoto","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s004280050149","article-title":"Comparison of Matrix Metalloproteinase Expression in Normal and Cirrhotic Human Liver","volume":"432","author":"Lichtinghagen","year":"1998","journal-title":"Virchows Arch"},{"key":"B49","first-page":"77","article-title":"The Association of MMP-1, -3 and -9 Genotypes With the Prognosis of HCV-Related Hepatocellular Carcinoma Patients","author":"Okamoto","year":"2005","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.3268","article-title":"The Genotypes of IL-1 Beta and MMP-3 Are Associated With the Prognosis of HCV-Related Hepatocellular Carcinoma","volume":"49","author":"Okamoto","year":"2010","journal-title":"Intern Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines; Management of Cholestatic Liver Diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients With Primary Biliary Cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.66397812","article-title":"Matrix Metalloproteinase 3: A Promoting and Destabilizing Factor in the Pathogenesis of Disease and Cell Differentiationuly","volume":"12","author":"Wan","year":"2021","journal-title":"Front Physiol"},{"key":"B54","article-title":"Elevated Plasma Stromelysin Levels in Arthritis","volume":"21","author":"Zucker","year":"1994","journal-title":"J Rheumatol"},{"key":"B55","article-title":"Increased Levels of Matrix Metalloproteinase-3 in Sera From Patients With Active Lupus Nephritis","volume":"16","author":"Kotajima","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.01.006","article-title":"MMP3 is a Reliable Marker for Disease Activity, Radiological Monitoring, Disease Outcome Predictability, and Therapeutic Response in Rheumatoid Arthritis","volume":"32","author":"Lernera","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/94065","article-title":"Matrix Metalloproteinase-3 Levels in Relation to Disease Activity and Radiological Progression in Rheumatoid Arthritis","volume":"28","author":"Tuncer","year":"2019","journal-title":"Adv Clin Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/151258","article-title":"Clinical Study Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls","volume":"2011","author":"Luckman","year":"2011","journal-title":"Autoimmune Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.53231","article-title":"The Role of Long-Term Doxycycline in Patients of Idiopathic Pulmonary Fibrosis: The Results of an Open Prospective Trial","volume":"26","author":"Bhattacharyya","year":"2009","journal-title":"Lung India"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-010-2816-x","article-title":"High Serum Matrix Metalloproteinase-3 and Liver Stiffness in Postoperative Biliary Atresia","volume":"27","author":"Honsawek","year":"2011","journal-title":"Pediatr Surg Int"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-Up Study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase","volume":"115","author":"Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.yexcr.2005.03.021","article-title":"Generation of Biologically Active Endostatin Fragments From Human Collagen XVIII by Distinct Matrix Metalloproteases","volume":"307","author":"Heljasvaara","year":"2005","journal-title":"Exp Cell Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.102814","article-title":"Soluble Endostatin Is a Novel Inhibitor of Epithelial Repair in Idiopathic Pulmonary Fibrosis","volume":"64","author":"Richter","year":"2009","journal-title":"Thorax"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.003","article-title":"Expression of MMP and TIMP in Liver Fibrosis - A Systematic Review With Special Emphasis on Anti-Fibrotic Strategies","volume":"46","author":"Hemmann","year":"2007","journal-title":"J Hepatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.06.041","article-title":"Matrix Metalloproteinase 3 Is a Mediator of Pulmonary Fibrosis","volume":"179","author":"Yamashita","year":"2011","journal-title":"Am J Pathol.;"},{"key":"B67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/1817-1737.105718","article-title":"Multiplex Protein Profiling of Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis and Hypersensitivity Pneumonitis","volume":"8","author":"Willems","year":"2013","journal-title":"Ann Thorac Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.3390\/molecules24224188","article-title":"The Comprehensive Role of Matrix Metalloproteinase in a Variety of Fibrosis Treatment Outcomes","volume":"24","author":"Chuang","year":"2019","journal-title":"Molecules"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.885229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T01:37:15Z","timestamp":1650591435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.885229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2022.885229"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.885229","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"article-number":"885229"}}